LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.
Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.
Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.
Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.
CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model.

item 1.01item 2.01item 3.02item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.